Peptide · developed by Novo Nordisk
NNC0194-0499 (also coded NNC0194) is a drug given subcutaneously. It is studied in alcohol-related liver disease.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06409130 | Phase 2 | Alcohol-related Liver Disease | Completed | NVO |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Alcohol-related Liver Disease
Updated Nov 22, 2026. Something wrong or missing? Report it on the NVO page.
See NVO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
NVO catalysts and pipeline →